English
SpanishTrusted Resources: News & Meetings
Latest announcements and gatherings
Viridian Announces Positive Data From Ongoing Phase 1/2 Trial Evaluating VRDN-001 in Patients With Thyroid Eye Disease (TED)
Viridian Therapeutics, Inc., a biotechnology company advancing new treatments for patients suffering from serious diseases underserved by current therapies, today announced positive topline clinical data from the first two cohorts in its ongoing Phase 1/2 clinical trial of VRDN-001, an anti-IGF-1R antibody, in patients with active thyroid eye disease (TED). TED is a rare autoimmune disease in which the body’s own immune system attacks the tissues around and behind the eyes causing inflammation, swelling, and damage that develops into debilitating signs and symptoms including double vision, bulging eyes, and ocular pain.
“These additional Phase 1/2 clinical data continue to support the potential for VRDN-001 to be a new treatment option for patients suffering from TED,” said Raymond Douglas, M.D., Ph.D., director of the Orbital and Thyroid Eye Disease Program, Cedars-Sinai Medical Center and an investigator on the VRDN-001 trial.
myBinderRelated Content
-
Johns Hopkins – Thyroid ClinicThe Johns Hopkins Division of Endocrinol...
-
Drug Effects on the ThyroidThe list of medications, many commonly u...
-
Debate Over Universal Screening for Thyroid Dysfunction in Pregnancy Centers on What to TreatThe question about screening for thyroid...
-
The University of Texas Southwestern Medical CenterThe specialized endocrinologists and end...
-
Hyperthyroidism: Graves’ OphthalmopathyGraves' ophthalmopathy, also called thyr...
-
Genetic Associations of the Thyroid Stimulating Hormone Receptor Gene With Graves’ Diseases and Graves’ ...Graves' disease (GD) is a common thyroid...
-
Thyroid Disease and Coronavirus (COVID-19)COVID-19 is a new illness that can affec...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Powered by
Brought to you by
Supported through an independent
educational grant by
